Navigation Links
Cranberry Capsule Proven to Cure Bladder Infection
Date:5/3/2012

AMSTERDAM, May 3, 2012 /PRNewswire/ --

Dutch Medical Brands receives first European Class IIa Medical Device Status

Instead of traditional treatment with antibiotics, bladder and urinary tract infections can be cured with cranberry capsules, without known side effects. Dutch company Medical Brands has obtained a Class IIa Medical Device Status for its patented Cranberry-Active capsule, making it the first and only cranberry-based product in Europe which has a proven medical claim.

Together with American company Decas Botanical Synergies (DBS), Medical Brands spent seven years developing the capsule and getting it patented and approved by the proper authorities.

While the claims of other cranberry-based food supplements will be rejected later this year by the European Food and Safety Authority (EFSA), Medical Brands produced studies which clinically showed that the capsule cures bladder infections. Compared to other cranberry products, MB and DBS developed a unique and proprietary formulation which is proven to treat and prevent bladder and urinary tract infections. It's the first capsule that can be freely sold as a medical device on the OTC market in all European countries.

"Bladder- and urinary tract infections (UTIs) are a serious health problem, affecting millions of people each year. Today, antibiotics are the traditional treatment for UTIs but there is a growing global push towards other solutions as resistance to antibiotics continues to rise. Our Cranberry-Active capsules marketing authorization is the culmination of years of planning, development and clinical investigation," says Maikel Hendriks, president of Medical Brands.

His company is specialised in developing medical devices without pharmacologic effects. It provides consumers with solutions for everyday diseases without the side effects most drugs have.

In the Netherlands the capsule is sold as the Bladder Infection Tablet by 'i say', in other countries Medical Brands is still searching for partners to sell the capsule. To inform potential market partners and consumers Medical Brands and DBS will present their Cranberry-Active capsules at the Vitafoods Europe 2012 conference in Geneva, Switzerland, at the Seminar Theater on Tuesday, May 22nd at 2:00 PM.


'/>"/>
SOURCE Medical Brands
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
2. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
3. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
4. Mayo Clinic Finds Capsule Endoscopy Can Detect Intestinal Damage Caused by Celiac Disease
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
7. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
8. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
9. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
10. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson ... Rio. Under the care of Maximized Living doctors at the London Olympics in ... Maximized Living is sending the largest contingent of elite chiropractors to Rio to support ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... by the Accreditation Council for Graduate Medical Education (ACGME) that it has received ... is the first accreditation of three residency programs that Memorial is currently pursuing, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... . Dr. Bernie Siegel, author of a plethora of essential books-to-read for ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):